6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity.
By R. Pellicciari, S. Fiorucci, E. Camaioni, C. Clerici, G. Costantino, P. Maloney, A. Morelli, D. Parks, T. Willson. Journal of Medicinal Chemistry, 2002
736 citations recorded by the source corpus.
Subfields: Oncology, Public Health, Environmental and Occupational Health, Surgery
View Paper: https://www.semanticscholar.org/paper/326ed7ad5b46891265d8d5df80e0f97cd6c1ea1f
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Oncology
In Surgery
Citations in the corpus
- Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. (2013, background): “Obeticholic acid (OCA; INT-747), a 6a-ethyl derivative of chenodeoxycholic acid, is a first-in-class selective FXR agonist with anticholestatic and hepatoprotective properties.(26) OCA shows 100-fold greater FXR agonistic activity than chenodeoxycholic acid, the natural FXR agonist in humans.”
- Role of bile acids and bile acid receptors in metabolic regulation. (2009, methodology): “thus classified as an agonist (EC50 8 M) (190, 232, 237, 359), DCA, LCA, and CA were inactive in this assay”
- A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. (2016, neutral): “Urinary tract infection 8 (11) 4 (6) 4 (5) 31 (16)”
- Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2018, background): “OCA is a Farnesoid X Receptor (FXR) agonist that is 100 times more potent than the endogenous ligand, chenodeoxycholic acid.(156) Through FXR activation, OCA modulates bile acid synthesis, absorption, transport, secretion, and metabolism, with a net effect of choleresis.”